Moderna Inc. (MRNA)
Moderna Swings to a Loss on Fewer Covid-19 Vaccine Sales
Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
Moderna: Focus On Cancer Vaccines, Not Buyout
Moderna surged on reports of talks with a large biopharma for a potential partnership or buyout, despite trading at multi-year lows. MRNA's promising cancer vaccine data and surprising findings on mRNA Covid vaccines boosting cancer survival rates drive renewed optimism for the drug pipeline. The company maintains a strong cash position, reduced costs, and a robust drug pipeline, with cancer vaccines representing the largest market opportunity.
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.
Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength?
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges
Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine maker's shares shoot higher.
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
Moderna (MRNA) reached $26.74 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
Moderna Vs BioNTech: Who's Winning The Post-COVID Race
Moderna and BioNTech were the main 'saviors' of people and economies from COVID-19. However, since the pandemic ended, their stock prices have fallen by more than 70%. Recognizing this, BioNTech and Moderna continue to actively diversify their portfolios of experimental drugs and vaccines toward cancer treatment.
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.
Moderna: Q3 Earnings Preview - I Fear A Halloween Horror Show (Downgrade)
Moderna, Inc. faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited pipeline progress. Moderna's cost-cutting measures and cash reserves provide a buffer, but lack of new product launches and market competition challenge near-term growth. Oncology pipeline, especially mRNA-4157 and mRNA-4359, offers long-term promise, but regulatory and reimbursement hurdles remain substantial.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Moderna (MRNA) stood at $27.92, denoting a +2.12% move from the preceding trading day.
